Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02766517 · ClinicalTrials.gov registry record · Early Phase 1
Biomarker Study in Participants With Migraine
A Early Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 37
- Enrollment target
NCT02766517 is a Early Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 37 participants.
The verdict
NCT02766517, a Early Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The study will last about five days.
Interventions
- DRUG Capsaicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2016-09-28 |
| Est. Completion | 2017-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02766517
The ClinicalTrials.gov registry entry for NCT02766517 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Capsaicin is the first listed.
NCT02766517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02766517 about?
NCT02766517 is a clinical study titled "Biomarker Study in Participants With Migraine". This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The stu...
What is the current status of trial NCT02766517?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 37 participants. The study started on 2016-09-28. Estimated completion is 2017-01-01.
What interventions are being tested in trial NCT02766517?
The interventions under investigation include: Capsaicin (DRUG).
Who is sponsoring clinical trial NCT02766517?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.